Full-Time
Confirmed live in the last 24 hours
Non-invasive cardiac testing for heart disease
$115k - $140kAnnually
Senior, Expert
Portland, OR, USA
Home-based position with up to 30-50% travel.
You match the following HeartFlow's candidate preferences
Employers are more likely to interview you if you match these preferences:
HeartFlow provides a non-invasive cardiac test that helps visualize a patient's coronary arteries in detail. This technology allows physicians to diagnose and treat heart disease more effectively without the need for invasive procedures, which reduces risks for patients and costs for healthcare providers. HeartFlow's main clients are healthcare professionals seeking safer diagnostic methods. The company offers several analyses, including FFRCT Analysis and Plaque Analysis, which have received FDA clearance and are available in the United States, the United Kingdom, Japan, and Canada. Unlike many competitors, HeartFlow focuses on non-invasive solutions that enhance treatment planning. The goal of HeartFlow is to improve cardiovascular care by making diagnosis and treatment safer and more efficient.
Company Size
501-1,000
Company Stage
Series F
Total Funding
$858.5M
Headquarters
Redwood City, California
Founded
2010
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Stock Options
401(k) Company Match
HeartFlow and Boone Heart Institute Launch GAMEFILM Registry to Study Heart Health in Retired NFL Players. by Fred Pennic 01/22/2025 Leave a Comment. What You Should Know: – HeartFlow, a global leader in AI-driven heart care solutions, and Boone Heart Institute, a renowned cardiovascular care provider in Denver, today announced the launch of the GAMEFILM Registry. – GAMEFILM Registry will utilize advanced imaging and AI technology to assess and better understand coronary artery disease (CAD) risk in retired National Football League (NFL) players.Understanding the Unique Cardiovascular Risks of Retired NFL PlayersCardiovascular disease remains the leading cause of death globally. Despite advancements in diagnostics, many heart attacks and strokes occur in individuals without prior symptoms. Early identification of high-risk individuals is critical for effective prevention and treatment. Retired NFL players often face unique cardiovascular health challenges due to the intense physical demands of their careers
HeartFlow announces new Category I CPT code from the American Medical Association for ai-enabled Plaque Analysis to assess risk for coronary artery disease.
HeartFlow launches plaque analysis platform for coronary artery disease.
Corcept appoints Monica Tellado as President, Emerging Markets.
Cardiovascular artificial intelligence (AI) software developer HeartFlow has released its RoadMap software for identifying stenoses in the coronary arteries on CT exams.
HeartFlow, Inc. announced the launch of the RoadMap analysis, a new AI -enabled product that assists CT readers to accurately*, efficiently, and consistently identify stenoses in the coronary arteries.
MOUNTAIN VIEW, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- HeartFlow, Inc. today announced the launch of the RoadMap analysis, a new AI-enabled product that assists CT readers to accurately*, efficiently, and consistently identify stenoses in the coronary arteries. With its expanded product portfolio, HeartFlow is now the only company to offer anatomical and physiological visualization of the coronary arteries to help improve heart disease diagnosis and enable physicians to guide treatment decisions. Heart disease is the leading cause of death in the United States.1 Despite advancements in the diagnosis and treatment of coronary artery disease (CAD), the most common heart disease, the complexities of symptoms and the limitations of traditional testing can make it challenging for physicians to correctly identify the condition. The RoadMap analysis is designed to help improve CAD diagnosis by providing CT readers with a 2D visual that shows the location and severity of anatomic narrowings in the coronary arteries. It has been shown to provide accurate*, reproducible results and helps facilitate standardized and high-quality CT interpretation.2 The RoadMap analysis, alongside HeartFlow’s FFRCT, aligns with the recently updated AHA/ACC chest pain guidelines and enhances existing diagnostic workflows by guiding treatment decisions and improving patient outcomes.3 “As a leader in non-invasive diagnosis of CAD, HeartFlow is intimately familiar with the challenges associated with diagnosing heart disease,” said John Farquhar, Chief Executive Officer of HeartFlow
MOUNTAIN VIEW, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced the close of a $215 million Series F funding round by its parent company HeartFlow Holding, Inc., led by Bain Capital Life Sciences with participation from new investor Janus Henderson Investors, and existing investors including Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP and Wellington Management. This new funding will enable HeartFlow to meet the growing demand for its commercial products, support a robust body of growing clinical evidence and advance its comprehensive product portfolio to help physicians to diagnose coronary artery disease (CAD) and guide their treatment decisions.The financing follows a period of remarkable growth for HeartFlow. Coronary computed tomography angiography (CCTA) and FFR CT have already been recognized by the recent ACC/AHA Chest Pain Guidelines, and HeartFlow's FFR CT technology is covered by 100% of Medicare and over 98% of commercial payers. With the recent FDA clearance of new products, the company is the first and only company to provide non-invasive coronary artery anatomy (RoadMap™ analysis), physiology (HeartFlow® FFR CT ) and plaque information (Plaque analysis) based on CCTA. These products enable physicians to gain more understanding of a patient's CAD and are the most comprehensive approach to predict risk of a heart attack.1"HeartFlow has built a strong intellectual property portfolio, brought to market the only combined anatomy, physiology and plaque analysis to help diagnose and treat heart disease, and is now in over 725 hospital systems worldwide with over 180,000 patients served to date," said John Farquhar, Chief Executive Officer of HeartFlow. "The oversubscription of our Series F funding round, particularly in the current market backdrop, is a strong validation of our technology, our team and the opportunity in front of us
HeartFlow Inc., a leader in precision heart care, has closed a $215 million Series F funding round by its parent company, HeartFlow Holding Inc. led by Bain Capital Life Sciences with participation from new investor, Janus Henderson Investors, and existing investors, including Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP and Wellington Management.
Financing will further drive commercial scale for HeartFlow’s AI-enabled portfolio of precision heart care products...
HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced that Monica Tellado has been appointed Chief Financial Officer (CFO), effective April 4, 2022.